News

GENOMEWEB | 08.29.19

Sema4 Lands New Investors, Continues to Expand

Sema4 has landed its first outside investment, allowing it to continue its rapid growth. Sema4 updated its investors webpage to include five new entities: private equity behemoth Blackstone; venture capital funds Section 32, OakHC/FT, and Decheng Capital; and Connecticut Innovations, the state’s quasi-public investment agency.
READ MORE
SEMA4 PRESS RELEASE | 08.01.19

Sema4 Announces Location of its Second Connecticut Lab

Sema4 announces location of its second Connecticut Lab as part of the company’s commitment to the state’s biotech industry. The new 70,000 square foot facility in Stamford will soon be home to 300+ employees. Governor Ned Lamont and U.S. Representative Jim Himes joined a ceremony on August 1st to commence construction.
READ MORE

SEMA4 PRESS RELEASE | 05.30.19

Sema4 Launches New Genomic Testing and Digital Tools for Use in Oncology

Sema4, a patient-centered health intelligence company, today announced the launch of several new genomic testing services and digital tools to help oncologists deliver on the promise of precision medicine. Together, these products provide a comprehensive approach that can be used throughout a patient’s journey, from assessing risk to analyzing cancer and monitoring in remission. Demonstrations of the products will be available at Sema4’s booth (#7140) at the American Society for Clinical Oncology 2019 Annual Meeting taking place in Chicago from May 31 to June 4.
READ MORE

FORBES | 04.08.19

Mother’s Day Gift Guide: Sema4 Natalis Newborn Screen, excellent idea for new moms

“When babies are born, hospitals screen for some genetic conditions, but would more in-depth testing provide greater peace of mind? New moms might appreciate the gift of at-home DNA screening through Sema4. The kit includes a simple cheek swab to collect a sample — no finger prick or blood draws needed!”
READ MORE
WIRED | 03.27.19

Sema4 provides women more personalized recommendations for accessing care

“For Sema4, reproductive genetic test are the foundation of an even more grandiose undertaking – collecting a universe of biodata so big and so powerful that it will blot out the one-size-fits-all model of care that has for so long dictated how doctors treat their patients…”
READ MORE
STAMFORD ADVOCATE | 12.6.18

Sema4 co-leads Asthma study with Sanofi

“Health care testing company Sema4 announced this week it would help launch an asthma study that aims to advance diagnoses and treatments of the chronic respiratory disease. Sema4, the Mount Sinai Health System and Sanofi are partnering on the five-year assessment of nearly 1,200 asthma patients in the U.S. to better understand the source of asthma attacks, the disease’s varying impact on patients, and the potential of certain therapies. For Sema4, the findings would help to develop asthma tests…”
READ MORE
FIERCE BIOTECH | 12.5.18

Sanofi, Sema4 Launch 5-Year, Real-World Digital Asthma Study

“Sanofi and Sema4 have launched a five-year longitudinal study of nearly 1,200 asthma patients, with plans to incorporate digital tools to develop a better understanding of the disease. Alongside collections of clinical, genomic and environmental data, it will employ connected inhalers to track how the disease affects some individuals differently than others, in what Sanofi describes as one of the largest studies of its kind…”
READ MORE
SEMA4 PRESS RELEASE | 12.04.18

Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind

“Sema4 and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors implicated in asthma. The project will follow nearly 1,200 people with asthma and collect a range of data — from traditional clinical data to genomics, immunological, environmental, and sensor data from mobile devices — to enable sophisticated analysis and advanced network modeling of this complex disease…”
READ MORE
CLINICALOMICS | 12.04.18

Sema4, Mt. Sinai Collaborate with Sanofi on Asthma Study

“Asthma is an incredibly complex condition associated with genetics, environmental factors, activity levels, the immune system, and more,” said Sema4 CEO, Eric Schadt… “We believe the only way to fully understand asthma is by using sophisticated modeling tools to mine the rich, multi-dimensional data set we aim to generate in this study.”
READ MORE
SEMA4 PRESS RELEASE | 10.25.18

Sema4 released results from proof-of-concept study: New Hope for Drug Discovery in Schizophrenia

“Scientists from the Icahn School of Medicine at Mount Sinai, Eli Lilly and Company, and Sema4 released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods. These findings could pave the way for streamlined drug discovery, particularly for diseases such as schizophrenia that have seen little therapeutic innovation…”
READ MORE